20,539 Shares in Lantheus Holdings, Inc. $LNTH Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 20,539 shares of the medical equipment provider’s stock, valued at approximately $2,273,000.

Other institutional investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its position in shares of Lantheus by 190.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after purchasing an additional 698 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Lantheus by 37.4% during the 2nd quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock worth $5,714,000 after purchasing an additional 19,008 shares during the last quarter. Baird Financial Group Inc. lifted its position in shares of Lantheus by 22.6% during the 2nd quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock worth $222,000 after purchasing an additional 500 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in shares of Lantheus by 88.1% during the second quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock worth $278,000 after purchasing an additional 1,591 shares in the last quarter. Finally, Osterweis Capital Management Inc. acquired a new position in shares of Lantheus during the second quarter worth $36,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. B. Riley Financial cut Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. Mizuho lowered their price objective on Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Wednesday, July 29th. Leerink Partners set a $102.50 price objective on Lantheus in a report on Monday, August 3rd. The Goldman Sachs Group reissued a “neutral” rating and set a $94.00 target price on shares of Lantheus in a research report on Thursday, May 7th. Finally, Wall Street Zen cut Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Four investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $108.11.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $100.77 on Monday. The stock has a market cap of $6.58 billion, a PE ratio of 24.34 and a beta of -0.03. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43. Lantheus Holdings, Inc. has a 52-week low of $49.67 and a 52-week high of $111.86. The business has a 50-day moving average price of $103.74 and a 200 day moving average price of $91.76.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. The firm had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.57 EPS. Equities research analysts forecast that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.